Contact

All Stories

  1. Synthetic opioids have disrupted conventional wisdom for treating opioid overdose

    Article • Drug and Alcohol Dependence Reports, September 2024, Elsevier

    Chief Scientific Officer Christian Heidbreder

  2. Editorial: Discovery, development and implementation of improved options for treating opioid overdose in the synthetic opioid era

    Article • Frontiers in Psychiatry, July 2024, Frontiers

    Chief Scientific Officer Christian Heidbreder

  3. A novel, non-opioid, selective orexin-1 receptor antagonist for the treatment of substance use disorders

    Article • Neuroscience Applied, January 2024, Elsevier

    Chief Scientific Officer Christian Heidbreder

  4. History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder

    Article • Drug and Alcohol Dependence Reports, March 2023, Elsevier

    Chief Scientific Officer Christian Heidbreder

  5. Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder

    Article • Frontiers in Pharmacology, November 2022, Frontiers

    Chief Scientific Officer Christian Heidbreder

  6. The introduction of a novel formulation of buprenorphine into organized health systems

    Article • Drug and Alcohol Dependence Reports, September 2022, Elsevier

    Chief Scientific Officer Christian Heidbreder

  7. Current Perspectives on Selective Dopamine D3 Receptor Antagonists/Partial Agonists as Pharmacotherapeutics for Opioid and Psychostimulant Use Disorders

    Article • January 2022, Springer Science + Business Media

    Chief Scientific Officer Christian Heidbreder

  8. Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS

    Article • Drug and Alcohol Dependence, December 2021, Elsevier

    Chief Scientific Officer Christian Heidbreder

  9. Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis

    Article • Journal of Clinical Psychopharmacology, May 2020, Wolters Kluwer Health

    Chief Scientific Officer Christian Heidbreder

  10. Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study

    Article • Journal of Addiction Medicine, March 2020, Wolters Kluwer Health

    Chief Scientific Officer Christian Heidbreder

  11. Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study

    Article • Journal of Substance Abuse Treatment, March 2020, Elsevier

    Chief Scientific Officer Christian Heidbreder

  12. Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study

    Article • Journal of Addiction Medicine, November 2019, Wolters Kluwer Health

    Chief Scientific Officer Christian Heidbreder

  13. Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia

    Article • Journal of Clinical Psychopharmacology, July 2019, Wolters Kluwer Health

    Chief Scientific Officer Christian Heidbreder

  14. Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study

    Article • Patient Preference and Adherence, July 2019, Dove Medical Press

    Susan Learned, Chief Scientific Officer Christian Heidbreder, Rahul Dhanda

  15. Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment

    Article • Substance Abuse and Rehabilitation, June 2019, Dove Medical Press

    Susan Learned, Chief Scientific Officer Christian Heidbreder

  16. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Article • The Lancet, February 2019, Elsevier

    Chief Scientific Officer Christian Heidbreder

  17. Remission from chronic opioid use—Studying environmental and socio-economic factors on recovery (RECOVER): Study design and participant characteristics

    Article • Contemporary Clinical Trials, January 2019, Elsevier

    Chief Scientific Officer Christian Heidbreder

  18. Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone

    Article • British Journal of Clinical Pharmacology, March 2017, Wiley

    Chief Scientific Officer Christian Heidbreder

  19. Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept

    Article • Journal of Pharmacy and Pharmacology, October 2016, Oxford University Press (OUP)

    Chief Scientific Officer Christian Heidbreder

  20. 1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists

    Article • Journal of Medicinal Chemistry, September 2016, American Chemical Society (ACS)

    Chief Scientific Officer Christian Heidbreder

  21. Quantitative determination of buprenorphine, naloxone and their metabolites in rat plasma using hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry

    Article • Biomedical Chromatography, August 2016, Wiley

    Chief Scientific Officer Christian Heidbreder

  22. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study

    Article • Schizophrenia Research, July 2016, Elsevier

    Chief Scientific Officer Christian Heidbreder

  23. Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia

    Article • Journal of Clinical Psychopharmacology, April 2016, Wolters Kluwer Health

    Chief Scientific Officer Christian Heidbreder

  24. 1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists

    Article • Bioorganic & Medicinal Chemistry, April 2016, Elsevier

    Chief Scientific Officer Christian Heidbreder

  25. Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder

    Article • The Journal of Clinical Pharmacology, March 2016, Wiley

    Chief Scientific Officer Christian Heidbreder

  26. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder

    Article • Journal of Clinical Psychopharmacology, February 2016, Wolters Kluwer Health

    Chief Scientific Officer Christian Heidbreder

  27. Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists

    Article • Bioorganic & Medicinal Chemistry Letters, February 2016, Elsevier

    Chief Scientific Officer Christian Heidbreder

  28. Simultaneous determination of buprenorphine, norbuprenorphine and naloxone in human plasma by liquid chromatography/tandem mass spectrometry

    Article • Journal of Pharmaceutical and Biomedical Analysis, February 2016, Elsevier

    Chief Scientific Officer Christian Heidbreder

  29. The selective dopamine D3 receptor antagonist SB‐277011A significantly accelerates extinction to environmental cues associated with cocaine‐induced place preference in male sprague‐dawley rats

    Article • Synapse, July 2015, Wiley

    Chief Scientific Officer Christian Heidbreder

  30. The selective dopamine D3 receptor antagonist SB‐277011A attenuates drug‐ or food‐deprivation reactivation of expression of conditioned place preference for cocaine in male sprague‐dawley rats

    Article • Synapse, April 2015, Wiley

    Chief Scientific Officer Christian Heidbreder

  31. Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers

    Article • Clinical Pharmacokinetics, January 2015, Springer Science + Business Media

    Chief Scientific Officer Christian Heidbreder

  32. A Randomized, Double-Blind, Placebo-Controlled Trial of RBP-8000 in Cocaine Abusers: Pharmacokinetic Profile of RBP-8000 and Cocaine and Effects of RBP-8000 on Cocaine-Induced Physiological Effects

    Article • Journal of Addictive Diseases, October 2014, Taylor & Francis

    Chief Scientific Officer Christian Heidbreder

  33. Population pharmacokinetic modeling and simulation to guide dose selection for RBP‐7000, a new sustained‐release formulation of risperidone

    Article • The Journal of Clinical Pharmacology, July 2014, Wiley

    Chief Scientific Officer Christian Heidbreder

  34. A Population Pharmacokinetic and Pharmacodynamic Modelling Approach to Support the Clinical Development of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Dependence

    Article • Clinical Pharmacokinetics, July 2014, Springer Science + Business Media

    Chief Scientific Officer Christian Heidbreder

  35. Liquid chromatography/tandem mass spectrometry method for simultaneous determination of cocaine and its metabolite (−)ecgonine methyl ester in human acidified stabilized plasma samples

    Article • Journal of Chromatography B, June 2014, Elsevier

    Chief Scientific Officer Christian Heidbreder

  36. Pharmacologically, are smokers the same as non-smokers?

    Article • Current Opinion in Pharmacology, February 2014, Elsevier

    Chief Scientific Officer Christian Heidbreder

  37. Population Pharmacokinetics and Prediction of Dopamine D2 Receptor Occupancy After Multiple Doses of RBP‐7000, a New Sustained‐Release Formulation of Risperidone, in Schizophrenia Patients on Stable Oral Risperidone Treatment

    Article • Clinical Pharmacokinetics, January 2014, Springer Science + Business Media

    Chief Scientific Officer Christian Heidbreder

  38. A model‐based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP‐7000, a new, long‐acting, sustained‐released formulation of risperidone

    Article • The Journal of Clinical Pharmacology, July 2013, Wiley

    Chief Scientific Officer Christian Heidbreder

  39. The selective D3receptor antagonist SB-277011A attenuates morphine-triggered reactivation of expression of cocaine-induced conditioned place preference

    Article • Synapse, March 2013, Wiley

    Chief Scientific Officer Christian Heidbreder

  40. Dopamine D3 receptor antagonists: a patent review (2007 – 2012)

    Article • Expert Opinion on Therapeutic Patents, January 2013, Informa Healthcare

    Chief Scientific Officer Christian Heidbreder

  41. Rationale in support of the use of selective dopamine D3 receptor antagonists for the pharmacotherapeutic management of substance use disorders

    Article • Naunyn-Schmiedeberg s Archives of Pharmacology, October 2012, Springer Science + Business Media

    Chief Scientific Officer Christian Heidbreder

  42. Occupancy of Brain Dopamine D3 Receptors and Drug Craving: A Translational Approach

    Article • Neuropsychopharmacology, September 2012, Springer Science + Business Media

    Chief Scientific Officer Christian Heidbreder

  43. The acute administration of the selective dopamine D3 receptor antagonist SB‐277011A reverses conditioned place aversion produced by naloxone precipitated withdrawal from acute morphine administration in rats

    Article • Synapse, November 2011, Wiley

    Chief Scientific Officer Christian Heidbreder

  44. The AVPR1A Gene and Substance Use Disorders: Association, Replication, and Functional Evidence

    Article • Biological Psychiatry, September 2011, Elsevier

    Chief Scientific Officer Christian Heidbreder

  45. Orexin-1 receptor antagonist SB-334867 reduces the acquisition and expression of cocaine-conditioned reinforcement and the expression of amphetamine-conditioned reward

    Article • Behavioural Pharmacology, April 2011, Wolters Kluwer Health

    Chief Scientific Officer Christian Heidbreder

  46. The GABA-B positive modulator GS39783 decreases psychostimulant conditioned-reinforcement and conditioned-reward

    Article • Addiction Biology, February 2011, Wiley

    Chief Scientific Officer Christian Heidbreder

  47. Advances in Animal Models of Drug Addiction

    Article • January 2011, Springer Science + Business Media

    Chief Scientific Officer Christian Heidbreder

  48. Exploration of the Amine Terminus in a Novel Series of 1,2,4-Triazolo-3-yl-azabicyclo[3.1.0]hexanes as Selective Dopamine D3 Receptor Antagonists

    Article • Journal of Medicinal Chemistry, September 2010, American Chemical Society (ACS)

    Chief Scientific Officer Christian Heidbreder

  49. [3-Azabicyclo[3.1.0]hex-1-yl]phenyl-benzenesulfonamides as selective dopamine D3 antagonists

    Article • Bioorganic & Medicinal Chemistry Letters, September 2010, Elsevier

    Chief Scientific Officer Christian Heidbreder

  50. Further considerations on the evaluation of potential reduced-risk tobacco products. Part II: Re-assessment of a heuristic using the CPS-II database

    Article • Regulatory Toxicology and Pharmacology, June 2010, Elsevier

    Chief Scientific Officer Christian Heidbreder

  51. Hypotheses and fundamental study design characteristics for evaluating potential reduced-risk tobacco products. Part I: Heuristic

    Article • Regulatory Toxicology and Pharmacology, June 2010, Elsevier

    Chief Scientific Officer Christian Heidbreder

  52. Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders

    Article • Annals of the New York Academy of Sciences, February 2010, Wiley

    Chief Scientific Officer Christian Heidbreder

  53. The orexin-1 receptor antagonist SB-334867 reduces amphetamine-evoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitization

    Article • Neurochemistry International, January 2010, Elsevier

    Chief Scientific Officer Christian Heidbreder

  54. 1,2,4-Triazolyl Azabicyclo[3.1.0]hexanes: A New Series of Potent and Selective Dopamine D3 Receptor Antagonists

    Article • Journal of Medicinal Chemistry, November 2009, American Chemical Society (ACS)

    Chief Scientific Officer Christian Heidbreder

  55. Chronic fluoxetine differentially modulates the hippocampal microtubular and serotonergic system in grouped and isolation reared rats

    Article • European Neuropsychopharmacology, November 2009, Elsevier

    Chief Scientific Officer Christian Heidbreder

  56. Light and intermittent cigarette smokers: a review (1989–2009)

    Article • Psychopharmacology, October 2009, Springer Science + Business Media

    Chief Scientific Officer Christian Heidbreder

  57. Dopamine D3 receptor antagonists: The quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies

    Article • Bioorganic & Medicinal Chemistry Letters, September 2009, Elsevier

    Chief Scientific Officer Christian Heidbreder

  58. Dopamine D3 receptor antagonists: The quest for a potentially selective PET ligand. Part one: Lead identification

    Article • Bioorganic & Medicinal Chemistry Letters, August 2009, Elsevier

    Chief Scientific Officer Christian Heidbreder

  59. Dopamine D3 receptor antagonists: The quest for a potentially selective PET ligand. Part two: Lead optimization

    Article • Bioorganic & Medicinal Chemistry Letters, August 2009, Elsevier

    Chief Scientific Officer Christian Heidbreder

  60. Delay of Ejaculation Induced by SB-277011, a Selective Dopamine D3 Receptor Antagonist, in the Rat

    Article • The Journal of Sexual Medicine, April 2009, Oxford University Press (OUP)

    Chief Scientific Officer Christian Heidbreder

  61. Systemic administration of ghrelin increases extracellular dopamine in the shell but not the core subdivision of the nucleus accumbens

    Article • Neurochemistry International, February 2009, Elsevier

    Chief Scientific Officer Christian Heidbreder

  62. Fluoxetine administration modulates the cytoskeletal microtubular system in the rat hippocampus

    Article • Synapse, January 2009, Wiley

    Chief Scientific Officer Christian Heidbreder

  63. Selective Antagonism at Dopamine D3 Receptors as a Target for Drug Addiction Pharmacotherapy: A Review of Preclinical Evidence

    Article • CNS & Neurological Disorders - Drug Targets, November 2008, Bentham Science Publishers

    Chief Scientific Officer Christian Heidbreder

  64. The effects of two highly selective dopamine D3 receptor antagonists (SB-277011A and NGB-2904) on food self-administration in a rodent model of obesity

    Article • Pharmacology Biochemistry and Behavior, June 2008, Elsevier

    Chief Scientific Officer Christian Heidbreder

  65. New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-Fused and hetero-fused systems

    Article • Bioorganic & Medicinal Chemistry Letters, February 2008, Elsevier

    Chief Scientific Officer Christian Heidbreder

  66. New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems

    Article • Bioorganic & Medicinal Chemistry Letters, February 2008, Elsevier

    Chief Scientific Officer Christian Heidbreder

  67. Impulse and Reward Deficit Disorders: Drug Discovery and Development

    Article • January 2008, Elsevier

    Chief Scientific Officer Christian Heidbreder

  68. Role of dopamine D3 receptors in the expression of conditioned fear in rats

    Article • European Journal of Pharmacology, January 2008, Elsevier

    Chief Scientific Officer Christian Heidbreder

  69. The effects of lamotrigine on alcohol seeking and relapse

    Article • Neuropharmacology, December 2007, Elsevier

    Chief Scientific Officer Christian Heidbreder

  70. The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats

    Article • Psychopharmacology, November 2007, Springer Science + Business Media

    Chief Scientific Officer Christian Heidbreder

  71. 1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines:  A Series of Potent and Selective Dopamine D3Receptor Antagonists

    Article • Journal of Medicinal Chemistry, October 2007, American Chemical Society (ACS)

    Chief Scientific Officer Christian Heidbreder

  72. Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d-amphetamine modified by selective dopamine D3 receptor antagonist SB277011A

    Article • Magnetic Resonance Imaging, July 2007, Elsevier

    Chief Scientific Officer Christian Heidbreder

  73. Dopamine D2 receptor stimulation inhibits cold-initiated thermogenesis in brown adipose tissue in conscious rats

    Article • Neuroscience, June 2007, Elsevier

    Chief Scientific Officer Christian Heidbreder

  74. Effects of the selective dopamine D3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats

    Article • European Journal of Pharmacology, March 2007, Elsevier

    Chief Scientific Officer Christian Heidbreder

  75. PRECLINICAL STUDY: Correlation between serum ghrelin levels and cocaine‐seeking behaviour triggered by cocaine‐associated conditioned stimuli in rats

    Article • Addiction Biology, February 2007, Wiley

    Chief Scientific Officer Christian Heidbreder

  76. PRECLINICAL STUDY: Evidence for the role of dopamine D3 receptors in oral operant alcohol self‐administration and reinstatement of alcohol‐seeking behavior in mice

    Article • Addiction Biology, February 2007, Wiley

    Chief Scientific Officer Christian Heidbreder

  77. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models

    Article • European Journal of Pharmacology, December 2006, Elsevier

    Chief Scientific Officer Christian Heidbreder

  78. Selective Dopamine D3 Receptor Antagonists: A Review 2001-2005

    Article • Recent Patents on CNS Drug Discovery, November 2006, Bentham Science Publishers

    Chief Scientific Officer Christian Heidbreder

  79. Isolation rearing induces recognition memory deficits accompanied by cytoskeletal alterations in rat hippocampus

    Article • European Journal of Neuroscience, November 2006, Wiley

    Chief Scientific Officer Christian Heidbreder

  80. Selective dopamine D3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases

    Article • Journal of Neuroscience Methods, October 2006, Elsevier

    Chief Scientific Officer Christian Heidbreder

  81. The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions

    Article • The International Journal of Neuropsychopharmacology, August 2006, Oxford University Press (OUP)

    Chief Scientific Officer Christian Heidbreder

  82. Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat

    Article • The International Journal of Neuropsychopharmacology, January 2006, Oxford University Press (OUP)

    Chief Scientific Officer Christian Heidbreder

  83. Selective down-regulation of [125I]Y0-α-conotoxin MII binding in rat mesostriatal dopamine pathway following continuous infusion of nicotine

    Article • Neuroscience, January 2006, Elsevier

    Chief Scientific Officer Christian Heidbreder

  84. Novel pharmacotherapeutic targets for the management of drug addiction

    Article • European Journal of Pharmacology, December 2005, Elsevier

    Chief Scientific Officer Christian Heidbreder

  85. Neuronal Plasticity, Stress and Depression: Involvement of the Cytoskeletal Microtubular System?

    Article • Current Drug Targets - CNS & Neurological Disorders, October 2005, Bentham Science Publishers

    Chief Scientific Officer Christian Heidbreder

  86. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex

    Article • Neuroscience Letters, October 2005, Elsevier

    Chief Scientific Officer Christian Heidbreder

  87. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence

    Article • Brain Research Reviews, July 2005, Elsevier

    Chief Scientific Officer Christian Heidbreder

  88. Selective dopamine D3 receptor antagonism by SB‐277011A attenuates cocaine reinforcement as assessed by progressive‐ratio and variable‐cost–variable‐payoff fixed‐ratio cocaine self‐administration in rats

    Article • European Journal of Neuroscience, June 2005, Wiley

    Chief Scientific Officer Christian Heidbreder

  89. Non-invasive in vivo infrared laser spectroscopy to analyse endogenous oxy-haemoglobin, deoxy-haemoglobin, and blood volume in the rat CNS

    Article • Journal of Neuroscience Methods, June 2005, Elsevier

    Chief Scientific Officer Christian Heidbreder

  90. The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats

    Article • Pharmacology Biochemistry and Behavior, May 2005, Elsevier

    Chief Scientific Officer Christian Heidbreder

  91. Acute administration of SB‐277011A, NGB 2904, or BP 897 inhibits cocaine cue‐induced reinstatement of drug‐seeking behavior in rats: Role of dopamine D3 receptors

    Article • Synapse, April 2005, Wiley

    Chief Scientific Officer Christian Heidbreder

  92. Postsynaptic 5‐HT1B receptors modulate electroshock‐induced generalised seizures in rats

    Article • British Journal of Pharmacology, March 2005, Wiley

    Chief Scientific Officer Christian Heidbreder

  93. Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving

    Article • Current Opinion in Pharmacology, February 2005, Elsevier

    Chief Scientific Officer Christian Heidbreder

  94. Recent Advances in the Pharmacotherapeutic Management of Drug Dependence and Addiction

    Article • Current Psychiatry Reviews, January 2005, Bentham Science Publishers

    Chief Scientific Officer Christian Heidbreder

  95. In vivo autofluorescence spectrofluorometry of central serotonin

    Article • Journal of Neuroscience Methods, December 2004, Elsevier

    Chief Scientific Officer Christian Heidbreder

  96. In vivo voltammetry: from wire to wireless measurements

    Article • Journal of Neuroscience Methods, December 2004, Elsevier

    Chief Scientific Officer Christian Heidbreder

  97. Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking

    Article • European Journal of Pharmacology, September 2004, Elsevier

    Chief Scientific Officer Christian Heidbreder

  98. Concurrent pharmacological MRI and in situ microdialysis of cocaine reveal a complex relationship between the central hemodynamic response and local dopamine concentration

    Article • NeuroImage, September 2004, Elsevier

    Chief Scientific Officer Christian Heidbreder

  99. High-performance liquid chromatography/tandem mass spectrometric assay for the simultaneous measurement of dopamine, norepinephrine, 5-hydroxytryptamine and cocaine in biological samples

    Article • Journal of Neuroscience Methods, September 2004, Elsevier

    Chief Scientific Officer Christian Heidbreder

  100. Rapid high-throughput assay for the measurement of amino acids from microdialysates and brain tissue using monolithic C18-bonded reversed-phase columns

    Article • Journal of Chromatography B, August 2004, Elsevier

    Chief Scientific Officer Christian Heidbreder

  101. Selective dopamine D3 receptor antagonist SB‐277011‐A potentiates phMRI response to acute amphetamine challenge in the rat brain

    Article • Synapse, July 2004, Wiley

    Chief Scientific Officer Christian Heidbreder

  102. Localisation of NMU1R and NMU2R in human and rat central nervous system and effects of neuromedin-U following central administration in rats

    Article • Psychopharmacology, June 2004, Springer Science + Business Media

    Chief Scientific Officer Christian Heidbreder

  103. Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats

    Article • Psychopharmacology, April 2004, Springer Science + Business Media

    Chief Scientific Officer Christian Heidbreder

  104. Role of dopamine D3 receptors in the addictive properties of ethanol

    Article • Drugs of Today, January 2004, Portico

    Chief Scientific Officer Christian Heidbreder

  105. Autofluorescence Spectrofluorometry of central nervous system (CNS) neuromediators

    Article • Lasers in Surgery and Medicine, January 2004, Wiley

    Chief Scientific Officer Christian Heidbreder

  106. LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease

    Article • Molecular and Cellular Neuroscience, December 2003, Elsevier

    Chief Scientific Officer Christian Heidbreder

  107. 5‐HT6 receptor antagonist SB‐271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex

    Article • Synapse, November 2003, Wiley

    Chief Scientific Officer Christian Heidbreder

  108. The medial prefrontal cortex in the rat: evidence for a dorso-ventral distinction based upon functional and anatomical characteristics

    Article • Neuroscience & Biobehavioral Reviews, October 2003, Elsevier

    Chief Scientific Officer Christian Heidbreder

  109. Dopamine responsiveness to drugs of abuse: A shell‐core investigation in the nucleus accumbens of the mouse

    Article • Synapse, September 2003, Wiley

    Chief Scientific Officer Christian Heidbreder

  110. Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in vitro and in vivo

    Article • Synapse, September 2003, Wiley

    Chief Scientific Officer Christian Heidbreder

  111. Gradient of dopamine responsiveness to dopamine receptor agonists in subregions of the rat nucleus accumbens

    Article • European Journal of Pharmacology, September 2003, Elsevier

    Chief Scientific Officer Christian Heidbreder

  112. Cytoskeletal changes in the hippocampus following restraint stress: Role of serotonin and microtubules

    Article • Synapse, May 2003, Wiley

    Chief Scientific Officer Christian Heidbreder

  113. Acute administration of the selective D3 receptor antagonist SB‐277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats

    Article • Synapse, March 2003, Wiley

    Chief Scientific Officer Christian Heidbreder

  114. Selective Antagonism at Dopamine D3 Receptors Prevents Nicotine-Triggered Relapse to Nicotine-Seeking Behavior

    Article • Neuropsychopharmacology, February 2003, Springer Science + Business Media

    Chief Scientific Officer Christian Heidbreder

  115. Amino acid neurotransmitters: separation approaches and diagnostic value

    Article • Journal of Chromatography B, December 2002, Elsevier

    Chief Scientific Officer Christian Heidbreder

  116. Selective Antagonism at Dopamine D3 Receptors Enhances Monoaminergic and Cholinergic Neurotransmission in the Rat Anterior Cingulate Cortex

    Article • Neuropsychopharmacology, November 2002, Springer Science + Business Media

    Chief Scientific Officer Christian Heidbreder

  117. High-performance liquid chromatography/tandem mass spectrometry assay for the rapid high sensitivity measurement of basal acetylcholine from microdialysates

    Article • Journal of Neuroscience Methods, November 2002, Elsevier

    Chief Scientific Officer Christian Heidbreder

  118. Sensitized Fos expression in subterritories of the rat medial prefrontal cortex and nucleus accumbens following amphetamine sensitization as revealed by stereology

    Article • Brain Research, September 2002, Elsevier

    Chief Scientific Officer Christian Heidbreder

  119. Development and application of a sensitive high performance ion-exchange chromatography method for the simultaneous measurement of dopamine, 5-hydroxytryptamine and norepinephrine in microdialysates from the rat brain

    Article • Journal of Neuroscience Methods, December 2001, Elsevier

    Chief Scientific Officer Christian Heidbreder

  120. Selective responding of nucleus accumbens core and shell dopamine to aversively conditioned contextual and discrete stimuli

    Article • Neuroscience, December 2001, Elsevier

    Chief Scientific Officer Christian Heidbreder

  121. Early social isolation, but not maternal separation, affects behavioral sensitization to amphetamine in male and female adult rats

    Article • Pharmacology Biochemistry and Behavior, October 2001, Elsevier

    Chief Scientific Officer Christian Heidbreder

  122. An automated analysis of rat behavior in the forced swim test

    Article • Pharmacology Biochemistry and Behavior, September 2001, Elsevier

    Chief Scientific Officer Christian Heidbreder

  123. In vivo characterization of basal amino acid levels in subregions of the rat nucleus accumbens: effect of a dopamine D3/D2 agonist

    Article • Neurochemistry International, September 2001, Elsevier

    Chief Scientific Officer Christian Heidbreder

  124. Increased responsiveness of dopamine to atypical, but not typical antipsychotics in the medial prefrontal cortex of rats reared in isolation

    Article • Psychopharmacology, June 2001, Springer Science + Business Media

    Chief Scientific Officer Christian Heidbreder

  125. Modulation of the Behavioral and Neurochemical Effects of Psychostimulants by κ‐Opioid Receptor Systems

    Article • Annals of the New York Academy of Sciences, June 2001, Wiley

    Chief Scientific Officer Christian Heidbreder

  126. Expression of sensitization to amphetamine and dynamics of dopamine neurotransmission in different laminae of the rat medial prefrontal cortex

    Article • Neuropharmacology, March 2001, Elsevier

    Chief Scientific Officer Christian Heidbreder

  127. Hyperactivity and disruption of prepulse inhibition induced by N-methyl-d-aspartate stimulation of the ventral hippocampus and the effects of pretreatment with haloperidol and clozapine

    Article • Neuroscience, March 2001, Elsevier

    Chief Scientific Officer Christian Heidbreder

  128. Acute withdrawal from repeated cocaine treatment enhances latent inhibition of a conditioned fear response

    Article • Behavioural Pharmacology, February 2001, Wolters Kluwer Health

    Chief Scientific Officer Christian Heidbreder

  129. Autoregulation of dopamine synthesis in subregions of the rat nucleus accumbens

    Article • European Journal of Pharmacology, January 2001, Elsevier

    Chief Scientific Officer Christian Heidbreder

  130. Behavioral, neurochemical and endocrinological characterization of the early social isolation syndrome

    Article • Neuroscience, October 2000, Elsevier

    Chief Scientific Officer Christian Heidbreder

  131. Differential involvement of dopamine in the shell and core of the nucleus accumbens in the expression of latent inhibition to an aversively conditioned stimulus

    Article • Neuroscience, May 2000, Elsevier

    Chief Scientific Officer Christian Heidbreder

  132. Effect of amphetamine on extracellular acetylcholine and monoamine levels in subterritories of the rat medial prefrontal cortex

    Article • European Journal of Pharmacology, February 2000, Elsevier

    Chief Scientific Officer Christian Heidbreder

  133. Differential role of the medial and lateral prefrontal cortices in fear and anxiety.

    Article • Behavioral Neuroscience, January 2000, American Psychological Association (APA)

    Chief Scientific Officer Christian Heidbreder

  134. Effects of administering cocaine at the same versus varying times of day on circadian activity patterns and sensitization in rats.

    Article • Behavioral Neuroscience, January 2000, American Psychological Association (APA)

    Chief Scientific Officer Christian Heidbreder

  135. Long-Lasting Effect of Early Handling on the Peripheral Benzodiazepine Receptor

    Article • Pharmacology Biochemistry and Behavior, December 1999, Elsevier

    Chief Scientific Officer Christian Heidbreder

  136. Amphetamine Microinfusion in the Dorso‐Ventral Axis of the Prefrontal Cortex Differentially Modulates Dopamine Neurotransmission in the Shell‐Core Subterritories of the Nucleus Accumbens

    Article • Annals of the New York Academy of Sciences, June 1999, Wiley

    Chief Scientific Officer Christian Heidbreder

  137. Effects of cocaine on dopamine in subregions of the rat prefrontal cortex and their efferents to subterritories of the nucleus accumbens

    Article • European Journal of Pharmacology, May 1999, Elsevier

    Chief Scientific Officer Christian Heidbreder

  138. Anticipatory responding, exclusive drug-context pairing and conditioned effects in sensitization to apomorphine-induced climbing in mice

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, April 1999, Elsevier

    Chief Scientific Officer Christian Heidbreder

  139. Dopamine and serotonin imbalances in the left anterior cingulate and pyriform cortices following the repeated intermittent administration of cocaine

    Article • Neuroscience, March 1999, Elsevier

    Chief Scientific Officer Christian Heidbreder

  140. Conditioning of and contextual sensitization to apomorphine-induced climbing in mice: Evidence against the habituation hypothesis.

    Article • Behavioral Neuroscience, January 1999, American Psychological Association (APA)

    Chief Scientific Officer Christian Heidbreder

  141. Behavioral neurochemistry reveals a new functional dichotomy in the shell subregion of the nucleus accumbens

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, January 1999, Elsevier

    Chief Scientific Officer Christian Heidbreder

  142. Amphetamine-induced neurochemical and locomotor responses are expressed differentially across the anteroposterior axis of the core and shell subterritories of the nucleus accumbens

    Article • Synapse, August 1998, Wiley

    Chief Scientific Officer Christian Heidbreder

  143. Long-Term Effects of Repeated Maternal Separation on Three Different Latent Inhibition Paradigms

    Article • Pharmacology Biochemistry and Behavior, April 1998, Elsevier

    Chief Scientific Officer Christian Heidbreder

  144. Evidence for an involvement of muscarinic cholinergic systems in the induction but not expression of behavioral sensitization to cocaine

    Article • Synapse, October 1996, Wiley

    Chief Scientific Officer Christian Heidbreder

  145. Differential role of δ-opioid receptors in the development and expression of behavioral sensitization to cocaine

    Article • European Journal of Pharmacology, March 1996, Elsevier

    Chief Scientific Officer Christian Heidbreder

  146. Sensitization to the conditioned rewarding effects of morphine: pharmacology and temporal characteristics

    Article • European Journal of Pharmacology, March 1996, Elsevier

    Chief Scientific Officer Christian Heidbreder

  147. The δ-opioid receptor antagonist naltrindole prevents sensitization to the conditioned rewarding effects of cocaine

    Article • European Journal of Pharmacology, June 1995, Elsevier

    Chief Scientific Officer Christian Heidbreder

  148. U-69593 prevents cocaine sensitization by normalizing basal accumbens dopamine

    Article • Neuroreport, September 1994, Wolters Kluwer Health

    Chief Scientific Officer Christian Heidbreder

  149. Ethanol differentially affects extracellular monoamines and GABA in the nucleus accumbens

    Article • Pharmacology Biochemistry and Behavior, October 1993, Elsevier

    Chief Scientific Officer Christian Heidbreder

  150. Inhibition of cocaine-induced sensitization by the δ-opioid receptor antagonist naltrindole

    Article • European Journal of Pharmacology, October 1993, Elsevier

    Chief Scientific Officer Christian Heidbreder

  151. The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat

    Article • Brain Research, July 1993, Elsevier

    Chief Scientific Officer Christian Heidbreder

  152. Enhancement of Mesolimbic Rewarding Brain Stimulation by Neurotensin Injected into the Accumbens, the Subiculum, or the Ventral Tegmental Area

    Article • Annals of the New York Academy of Sciences, October 1992, Wiley

    Chief Scientific Officer Christian Heidbreder

  153. Balance of glutamate and dopamine in the nucleus accumbens modulates self-stimulation behavior after injection of cholecystokinin and neurotensin in the rat brain

    Article • Peptides, May 1992, Elsevier

    Chief Scientific Officer Christian Heidbreder

  154. Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats

    Article • Pharmacology Biochemistry and Behavior, April 1992, Elsevier

    Chief Scientific Officer Christian Heidbreder

  155. Inhibition of enkephalin metabolism and activation of mu- or delta-opioid receptors elicit opposite effects on reward and motility in the ventral mesencephalon

    Article • Neuropharmacology, March 1992, Elsevier

    Chief Scientific Officer Christian Heidbreder

  156. Regional amines levels in the rat brain following intra-accumbens cholecystokinin and intraperitoneal amphetamine pre-treatment

    Article • Archives Internationales de Physiologie de Biochimie et de Biophysique, January 1992, Taylor & Francis

    Chief Scientific Officer Christian Heidbreder

  157. Differential effects of caerulein and bombesin on the ethanol intake in the rat

    Article • Archives Internationales de Physiologie de Biochimie et de Biophysique, January 1991, Taylor & Francis

    Chief Scientific Officer Christian Heidbreder

  158. ACAMPROSATE AND DIAZEPAM DIFFERENTIALLY MODULATE ALCOHOL-INDUCED BEHAVIOURAL AND CORTICAL ALTERATIONS IN RATS FOLLOWING CHRONIC INHALATION OF ETHANOL VAPOUR

    Article • Alcohol and Alcoholism, January 1991, Oxford University Press (OUP)

    Chief Scientific Officer Christian Heidbreder

  159. Intracranial Stimulation as Reinforcer for Neuropeptide Discrimination

    Article • January 1991, American Psychological Association (APA)

    Chief Scientific Officer Christian Heidbreder

  160. Cortical microvascular changes in chronological aging, cortical insults and chronic alcohol intoxication in rats. Effects of antihypoxic drug on these phenomena

    Article • Alcohol, November 1989, Elsevier

    Chief Scientific Officer Christian Heidbreder

  161. Kelatorphan, a potent enkephalinases inhibitor, and opioid receptor agonists DAGO and DTLET, differentially modulate self-stimulation behaviour depending on the site of administration

    Article • Neuropharmacology, July 1989, Elsevier

    Chief Scientific Officer Christian Heidbreder

  162. Similar potencies of CCK-8 and its analogue BOC(Nle28;Nle31)CCK27–33 on the self-stimulation behaviour both are antagonized by a newly synthesized cyclic CCK analogue

    Article • Neuropeptides, February 1989, Elsevier

    Chief Scientific Officer Christian Heidbreder

  163. Utilisation du conditionnement discriminatif en pharmacologie comportementale

    Article • L’Année psychologique, January 1989, PERSEE Program

    Chief Scientific Officer Christian Heidbreder

  164. Kelatorphan, a potent enkephalinases inhibitor, presents opposite properties when injected intracerebroventricularly or into the nucleus accumbens on intracranial self-stimulation

    Article • Neurochemistry International, January 1988, Elsevier

    Chief Scientific Officer Christian Heidbreder

  165. Opposite effects of cholecystokinin octapeptide (CCK-8) and tetrapeptide (CCK-4) after injection into the caudal part of the nucleus accumbens or into its rostral part and the cerebral ventricles

    Article • Neurochemistry International, January 1987, Elsevier

    Chief Scientific Officer Christian Heidbreder

  166. Molecular and Behavioral Aspects of Nicotine Dependence and Reward

    Article • Springer Science + Business Media

    Chief Scientific Officer Christian Heidbreder